ÂÜÀòÂÒÂ×

Christopher Mahn is a seasoned professional with extensive experience in program management within the biotechnology sector. As the Senior Director of Program Management at Neogene Therapeutics since August 2022, Christopher previously held similar roles at Ventyx Biosciences and Gossamer Bio, where responsibilities included leading complex projects in research and development. Prior positions include Director roles at Evofem Biosciences and Regulus Therapeutics, focusing on nonclinical and CMC functions, as well as program management at IriSys, LLC, where Christopher led the establishment of a new cGMP parenteral development unit. Christopher's academic background includes a Bachelor of Science in Earth Science from UC San Diego, alongside advanced studies in Marine Chemistry & Geochemistry at the Scripps Institution of Oceanography, complemented by a Biofuels Science Certificate.